Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination

An Open-Label Study to Examine the Long-Term Effect on Glucose Control (HbA1c) and Safety of AC2993 Given Two Times a Day to Subjects With Type 2 Diabetes Treated With Metformin, a Sulfonylurea, or Metformin and Sulfonylurea Combination

This multi-center, open-label study is designed to examine the effects on long-term glucose control and safety of AC2993 in patients with type 2 diabetes treated with metformin, sulfonylurea, or metformin and sulfonylurea combination.

Inclusion Criteria:

• Subjects with type 2 diabetes
• Treated for at least 3 months prior to screening either with metformin, sulfonylurea, or metformin and sulfonylurea combination
• BMI 25-45 kg/m^2
• HbA1c between 7.5 % and 12.0 %, inclusive

Exclusion Criteria:

• Treated with other oral anti-diabetic agents other than metformin and sulfonylureas within 3 months of screening
• Patients previously treated with AC2993
• Patients presently treated with insulin